FGFRL1 and lung cancer: This study demonstrated that CSCs, through the release of exosomes rich with miR-210-3p, induce a prometastatic phenotype in lung cancer cells, downregulating FGFRL1, which may act as a metastatic inhibitor, suggesting new possible therapeutic targets in lung cancer.